Franck Rouby
Assistance Publique Hôpitaux de Marseille(FR)Institut de Neurosciences des Systèmes(FR)Société du Canal de Provence(FR)
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, Drug-Induced Adverse Reactions, Colorectal Cancer Treatments and Studies, Chronic Lymphocytic Leukemia Research, Pharmacovigilance and Adverse Drug Reactions
Most-Cited Works
- → Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer(2020)121 cited
- → Thrombotic microangiopathy associated with gemcitabine use: Presentation and outcome in a national French retrospective cohort(2018)63 cited
- → Immune check point inhibitors-induced hypophysitis: a retrospective analysis of the French Pharmacovigilance database(2019)59 cited
- → Acute Coronary Syndrome With Immune Checkpoint Inhibitors: A Proof-of-Concept Case and Pharmacovigilance Analysis of a Life-Threatening Adverse Event(2019)50 cited
- → Artificial Intelligence for Unstructured Healthcare Data: Application to Coding of Patient Reporting of Adverse Drug Reactions(2021)44 cited
- → Occurrence of type 1 and type 2 diabetes in patients treated with immunotherapy (anti-PD-1 and/or anti-CTLA-4) for metastatic melanoma: a retrospective study(2018)36 cited